Figure 5. Analysis of the structure of laryngeal tumor cells before and after treatment by electron microscope. Upper panel: Normal structure of laryngeal tumor cells before treatment with MeV, nimotuzumab or MeV+nimotuzumab combination. (1), normal structure of laryngeal tumor cells; (2), nucleus; (3), mucous membrane; (4, 5), dividing cells. Middle panel: Structure of laryngeal tumor cells after treatment with MeV, nimotuzumab or MeV+nimotuzumab combination. (A), Untreated cells; (B), laryngeal tumor Hep2 cells infected with MeV; (C, D), syncytia of cells that result from cell fusions. Lower panel: (E), Hep2 laryngeal tumor cells with chromosome condensation; (F), Hep2 laryngeal tumor cells with chromosome fragmentation; (G), Hep2 laryngeal tumor cells with many vacuoles; (H), necrotizing cells.